Corrigendum: CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome

Choreño-Parra, Jose Alberto; Jiménez-Álvarez, Luis Armando; Ramírez-Martínez, Gustavo; Sandoval-Vega, Montserrat; Salinas-Lara, Citlaltepetl; Sánchez-Garibay, Carlos; Luna-Rivero, Cesar; Hernández-Montiel, Erika Mariana; Fernández-López, Luis Alejandro; Cabrera-Cornejo, María Fernanda; Choreño-Parra, Eduardo Misael; Cruz-Lagunas, Alfredo; Domínguez, Andrea; Márquez-García, Eduardo; Cabello-Gutiérrez, Carlos; Bolaños-Morales, Francina Valezka; Mena-Hernández, Lourdes; Delgado-Zaldivar, Diego; Rebolledo-García, Daniel; Guadarrama-Ortiz, Parménides; Regino-Zamarripa, Nora E.; Mendoza-Milla, Criselda; García-Latorre, Ethel A.; Rodríguez-Reyna, Tatiana Sofía; Cervántes-Rosete, Diana; Hernández-Cárdenas, Carmen M.; Khader, Shabaana A.; Zlotnik, Albert; Zúñiga, Joaquín

doi:10.3389/fimmu.2021.700716

CORRECTION article

Front. Immunol., 13 May 2021

Sec. Viral Immunology

Volume 12 - 2021 | https://doi.org/10.3389/fimmu.2021.700716

Corrigendum: CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome

This article is a correction to:

CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome
1. Read original article

Jose Alberto Choreño-Parra^1,2

Luis Armando Jiménez-Álvarez²

Gustavo Ramírez-Martínez²

Montserrat Sandoval-Vega³

Citlaltepetl Salinas-Lara⁴

Carlos Sánchez-Garibay⁴

Cesar Luna-Rivero⁵

Erika Mariana Hernández-Montiel^2,6

Luis Alejandro Fernández-López^1,2

María Fernanda Cabrera-Cornejo^2,6

Eduardo Misael Choreño-Parra⁷

Alfredo Cruz-Lagunas²

Andrea Domínguez^2,6

Eduardo Márquez-García²

Carlos Cabello-Gutiérrez⁸

Francina Valezka Bolaños-Morales⁹

Lourdes Mena-Hernández¹⁰

Diego Delgado-Zaldivar¹⁰

Daniel Rebolledo-García¹⁰

Parménides Guadarrama-Ortiz¹¹

Nora E. Regino-Zamarripa^1,2,6

Criselda Mendoza-Milla¹²

Ethel A. García-Latorre¹

Tatiana Sofía Rodríguez-Reyna¹³

Diana Cervántes-Rosete¹³

Carmen M. Hernández-Cárdenas¹⁴

Shabaana A. Khader¹⁵

Albert Zlotnik¹⁶

Joaquín Zúñiga^2,6*

¹Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico
²Laboratorio de Inmunobiología y Genética, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, Mexico City, Mexico
³Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Mexico City, Mexico
⁴Departamento de Neuropatología, Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suarez”, Mexico City, Mexico
⁵Department of Pathology, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, Mexico City, Mexico
⁶Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City, Mexico
⁷Posgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México, Mexico City, Mexico
⁸Department of Virology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
⁹Subdirection of Surgery, Instituto Nacional deEnfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
¹⁰Departments of Dermatology and Education, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
¹¹Centro Especializado en Neurocirugía y Neurociencias México (CENNM), Mexico City, Mexico
¹²Departamento de Fibrosis Pulmonar, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, Mexico City, Mexico
¹³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
¹⁴Respiratory Critical Care Unit, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
¹⁵Department of Molecular Microbiology, Washington University School of Medicine in St Louis, St. Louis, MO, United States
¹⁶Department of Physiology & Biophysics School of Medicine, Institute for Immunology, University of California, Irvine, CA, United States

A Corrigendum on
CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome

By Choreño-Parra JA, Jiménez-Álvarez LA, Ramírez-Martínez G, Sandoval-Vega M, Salinas-Lara C, Sánchez-Garibay C, Luna-Rivero C, Hernández-Montiel EM, Fernández-López LA, Cabrera-Cornejo MF, Choreño-Parra EM, Cruz-Lagunas A, Domínguez A, Márquez-García E, Cabello-Gutiérrez C, Bolaños-Morales FV, Mena-Hernández L, Delgado-Zaldivar D, Rebolledo-García D, Guadarrama-Ortiz P, Regino-Zamarripa NE, Mendoza-Milla C, García-Latorre EA, Rodríguez-Reyna TS, Cervántes-Rosete D, Hernández Cárdenas CM, Khader SA, Zlotnik A and Zúñiga J (2021). Front. Immunol. 12:633297. doi: .10.3389/fimmu.2021.633297

An author name was incorrectly spelled as Tatiana Sofia Rodiguez-Reyna. The correct spelling is Tatiana Sofía Rodríguez-Reyna.

In the published article, there was also an error in the affiliation of Criselda Mendoza-Milla. Instead of “Laboratorio de Inmunobiología y Genética, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, Mexico City, Mexico”, it should be “Departamento de Fibrosis Pulmonar, Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas”, Mexico City, Mexico”.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: influenza A(H1N1), SARS-CoV-2, COVID-19, tuberculosis, chemokines, CXCL17

Citation: Choreño-Parra JA, Jiménez-Álvarez LA, Ramírez-Martínez G, Sandoval-Vega M, Salinas-Lara C, Sánchez-Garibay C, Luna-Rivero C, Hernández-Montiel EM, Fernández-López LA, Cabrera-Cornejo MF, Choreño-Parra EM, Cruz-Lagunas A, Domínguez A, Márquez-García E, Cabello-Gutiérrez C, Bolaños-Morales FV, Mena-Hernández L, Delgado-Zaldivar D, Rebolledo-García D, Guadarrama-Ortiz P, Regino-Zamarripa NE, Mendoza-Milla C, García-Latorre EA, Rodríguez-Reyna TS, Cervántes-Rosete D, Hernández-Cárdenas CM, Khader SA, Zlotnik A and Zúñiga J (2021) Corrigendum: CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome. Front. Immunol. 12:700716. doi: 10.3389/fimmu.2021.700716

Received: 26 April 2021; Accepted: 27 April 2021;
Published: 13 May 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Choreño-Parra, Jiménez-Álvarez, Ramírez-Martínez, Sandoval-Vega, Salinas-Lara, Sánchez-Garibay, Luna-Rivero, Hernández-Montiel, Fernández-López, Cabrera-Cornejo, Choreño-Parra, Cruz-Lagunas, Domínguez, Márquez-García, Cabello-Gutiérrez, Bolaños-Morales, Mena-Hernández, Delgado-Zaldivar, Rebolledo-García, Guadarrama-Ortiz, Regino-Zamarripa, Mendoza-Milla, García-Latorre, Rodríguez-Reyna, Cervántes-Rosete, Hernández-Cárdenas, Khader, Zlotnik and Zúñiga. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Joaquín Zúñiga, joazu@yahoo.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.